Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 138

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 138
---
 develop customized fertility benefit programs that cater to their specific needs, and to provide comprehensive support
and counselling throughout the process.

Meanwhile, NewGenIvf also
intends to attract more clients by establishing its “home country gynecologist partnership program”. Under the program, NewGenIvf
may, subject to its discretion and screening process, offer treatment services to clients with reduced time requirements to be spent
overseas. Depending on local laws, the potential clients may be able to complete their treatments with gynecologists NewGenIvf partners
with, in their home countries.

<div align='center'>81</div>

NewGenIvf had entered
into a non-binding term sheet dated June 3, 2024 (the “Term Sheet”) with COVIRIX Medical Pty Ltd (“COVIRIX”)
for a proposed reverse merger (the “Proposed Transaction”). However, on September 21, 2024, COVIRIX withdrew from the Proposed
Transaction, as such the Proposed Transaction was terminated with no cost to the Company. On December 11, 2024, NewGenIvf also announced
its entry into a binding term sheet with European Wellness Investment Holdings Limited (“EWIHL”) for a proposed reverse merger
(“EWIHL Proposed Transaction”), completion of which was subject to, among other conditions, the completion of due diligence,
the negotiation of a definitive agreement, and obtaining adequate financing. On March 31, 2025, NewGenIvf terminated the term sheet for
the EWIHL Proposed Transaction as EWIHL had failed to produce certain draft audited financials, which were specifically required in the
term sheet.

On February 28, 2025,
NewGenIvf completed its acquisition of the MicroSort technology from Genetics & IVF Institute, Inc. (“GIVF”). Pursuant
to a Purchase Agreement dated January 21, 2025 between NewGenIvf and GIVF (“Purchase Agreement”), NewGenIvf purchased all
of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort
technology (as described below from GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Class A Ordinary Shares
(equivalent to 12,500 Class A Ordinary Shares post Second Reverse Stock Split) (“MicroSort Acquisition”).

White Lion Transaction

On November 21, 2024,